Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Prostate
• Age: Between 18 Year(s) - 99 Year(s)
• Gender: Male

• Other Inclusion Criteria:
  

  In order to participate in this study the following conditions must be met:

  1. Participant must be an adult male patients =18 years of age.
  2. An Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) =2.
  3. Histological and/or cytological confirmation of adenocarcinoma of the prostate.

  
  

You may not be eligible for this study if the following are true:

• You will not be able to participate in this study if you have:

  1. Ongoing participation in any other interventional trial.
  2. Any investigational agents received within 28 days (or 5 half-lives, whichever is longer) prior to randomization.
  3. Participants with biochemical recurrence only or those without evidence of metastatic disease by radiographical imaging (CT/MRI or bone scan).
  4. Prior exposure to a second generation ARPI (such as enzalutamide/darolutamide/apalutamide and/or abiraterone) for the treatment of advanced/metastatic disease is not allowed. Prior exposure to a second generation ARPI, to taxane chemotherapy (up to 6 cycles) or to RLT in the context of (neo)adjuvant treatment for localized prostate cancer is allowed, if the last dose of this treatment was administered >12 months from randomization.